Hormonal
Lisdexamfetamine dimesylate is the only FDA-approved medication for Binge Eating Disorder and significantly reduces binge eating days and increases binge cessation rates compared to placebo.
Lisdexamfetamine is the only FDA-approved medication for Binge Eating Disorder. Clinical trials show it significantly reduces binge eating days and increases the likelihood of stopping binges compared to a placebo. However, because it is a stimulant, it requires caution in patients with T2DM who may also have hypertension or cardiovascular issues. Discuss the risks and benefits with your doctor if you are considering medication.
The only current Food and Drug Administration (FDA) approved medication for the treatment of BED is the stimulant lisdexamfetamine... the medication decreased binge eating days, binge-eating related obsessions and compulsions, and more frequently resulted in binge cessation than placebo.
Why this rating
Supported by multiple multicenter, double-blind trials and meta-analyses.
Source
<p>Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges</p>
Jonathan D Chevinsky et al. · Diabetes Metabolic Syndrome and Obesity · 2020
DOI 10.2147/dmso.s213379
More from this paper
- Cognitive Behavioral Therapy (CBT) is the current treatment of choice for Binge Eating Disorder and is effective in reducing binge frequency and achieving remission, though it may not significantly reduce weight.Strong
- Binge Eating Disorder (BED) in patients with Type 2 Diabetes (T2DM) is associated with poorer glycemic control, specifically higher HbA1c levels and increased insulin resistance, independent of BMI in some contexts.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →